AbbVie Inc (ABBV)vsXWELL Inc. (XWEL)
ABBV
AbbVie Inc
$264.02
+0.58%
HEALTHCARE · Cap: $454.36B
XWEL
XWELL Inc.
$0.91
0.00%
HEALTHCARE · Cap: $8.93M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 227557% more annual revenue ($64.39B vs $28.28M). ABBV leads profitability with a 9.8% profit margin vs -82.9%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
XWEL
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.5%
Fair Value
$152.16
Current Price
$264.02
$111.86 premium
Margin of Safety
+57.2%
Fair Value
$0.92
Current Price
$0.91
$0.02 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 18.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : XWEL
The strongest argument for XWEL centers on Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : XWEL
The primary concerns for XWEL are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
ABBV profiles as a value stock while XWEL is a turnaround play — different risk/reward profiles.
XWEL carries more volatility with a beta of 1.01 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 22/100) and 10.2% revenue growth. XWEL offers better value entry with a 57.2% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
XWELL Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
XWELL Inc., a health and wellness services company, provides spa services at airports. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?